A Systematic Evaluation of Effect of Adherence Patterns on the Sample Size and Power of a Clinical Study

Overview

Journal CPT Pharmacometrics Syst Pharmacol

Publisher Wiley

Specialty Pharmacology

Date 2018 Oct 7

PMID 30291680

Citations 9

Authors

Surulivelrajan Mallayasamy

Ayyappa Chaturvedula

Terrence Blaschke

Michael J Fossler

Affiliations

Soon will be listed here.

Abstract

The objective of our study was to evaluate the effect of adherence patterns on the sample size and power of a clinical trial. Simulations from a population pharmacokinetic/pharmacodynamic (PK/PD) model linked to an adherence model were used. Four types of drug characteristics, such as long (~35 hours) and short (~12 hours) half-life in combination with earlier or delayed time to reach steady-state PD end points were studied. Adherence patterns were simulated using Markov chains. Our results clearly demonstrate the significant impact of varying levels and patterns of nonadherence on the sample size and power of a study. For drugs with short half-lives the evidence to support efficacy could be diluted by various patterns of nonadherence that would make its efficacy indistinguishable from the response to placebo. Prospectively utilizing clinical trial simulations with thorough incorporation of various adherence patterns would provide valuable information when designing a trial.

Citing Articles

Mathematical models of Plasmodium vivax transmission: A scoping review.

Anwar M, Smith L, Devine A, Mehra S, Walker C, Ivory E PLoS Comput Biol. 2024; 20(3):e1011931.

PMID: 38483975 PMC: 10965096. DOI: 10.1371/journal.pcbi.1011931.

Pairwise comparisons of three medication adherence outcomes in adolescents who use alcohol.

Kirkland A, Tomko R, Green R, Browning B, Ferguson P, Liu H Alcohol Clin Exp Res (Hoboken). 2023; 47(12):2375-2385.

PMID: 38151786 PMC: 10755249. DOI: 10.1111/acer.15216.

Leveraging mathematical modeling to analyze nonadherence for hydroxyurea therapy in sickle cell disease.

Pandey A, Raja R, Estepp J, Ramkrishna D CPT Pharmacometrics Syst Pharmacol. 2023; 12(6):748-757.

PMID: 37194405 PMC: 10272301. DOI: 10.1002/psp4.12945.

A genome-wide association study of plasma concentrations of warfarin enantiomers and metabolites in sub-Saharan black-African patients.

Asiimwe I, Blockman M, Cohen K, Cupido C, Hutchinson C, Jacobson B Front Pharmacol. 2022; 13:967082.

PMID: 36210801 PMC: 9537548. DOI: 10.3389/fphar.2022.967082.

Patient-Reported Outcomes as Endpoints in Clinical Trials of Kidney Transplantation Interventions.

Tong A, Oberbauer R, Bellini M, Budde K, Caskey F, Dobbels F Transpl Int. 2022; 35:10134.

PMID: 35669971 PMC: 9163311. DOI: 10.3389/ti.2022.10134.

References

Vrijens B, Urquhart J . Methods for measuring, enhancing, and accounting for medication adherence in clinical trials. Clin Pharmacol Ther. 2014; 95(6):617-26. DOI: 10.1038/clpt.2014.59. View

Blaschke T, Osterberg L, Vrijens B, Urquhart J . Adherence to medications: insights arising from studies on the unreliable link between prescribed and actual drug dosing histories. Annu Rev Pharmacol Toxicol. 2011; 52:275-301. DOI: 10.1146/annurev-pharmtox-011711-113247. View

Akacha M, Kothny W . Estimands: A More Strategic Approach to Study Design and Analysis. Clin Pharmacol Ther. 2017; 102(6):894-896. DOI: 10.1002/cpt.872. View

Sharma V, Combes F, Vakilynejad M, Lahu G, Lesko L, Trame M . Model-Based Approach to Predict Adherence to Protocol During Antiobesity Trials. J Clin Pharmacol. 2017; 58(2):240-253. PMC: 5811797. DOI: 10.1002/jcph.994. View

. Influence of adherence to treatment and response of cholesterol on mortality in the coronary drug project. N Engl J Med. 1980; 303(18):1038-41. DOI: 10.1056/NEJM198010303031804. View

Fossler M . Patient adherence: clinical pharmacology's embarrassing relative. J Clin Pharmacol. 2014; 55(4):365-7. DOI: 10.1002/jcph.426. View

Kenna L, Labbe L, Barrett J, Pfister M . Modeling and simulation of adherence: approaches and applications in therapeutics. AAPS J. 2005; 7(2):E390-407. PMC: 2750977. DOI: 10.1208/aapsj070240. View

Nedelman J . On some "disadvantages" of the population approach. AAPS J. 2005; 7(2):E374-82. PMC: 2750975. DOI: 10.1208/aapsj070238. View

Sullivan G, Feinn R . Using Effect Size-or Why the P Value Is Not Enough. J Grad Med Educ. 2013; 4(3):279-82. PMC: 3444174. DOI: 10.4300/JGME-D-12-00156.1. View

10.

Kastrissios H, Suarez J, Katzenstein D, Girard P, Sheiner L, Blaschke T . Characterizing patterns of drug-taking behavior with a multiple drug regimen in an AIDS clinical trial. AIDS. 1998; 12(17):2295-303. DOI: 10.1097/00002030-199817000-00011. View

11.

Marin D, Bazeos A, Mahon F, Eliasson L, Milojkovic D, Bua M . Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib. J Clin Oncol. 2010; 28(14):2381-8. PMC: 6366340. DOI: 10.1200/JCO.2009.26.3087. View

12.

Thigpen M, Kebaabetswe P, Paxton L, Smith D, Rose C, Segolodi T . Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana. N Engl J Med. 2012; 367(5):423-34. DOI: 10.1056/NEJMoa1110711. View

13.

Castillo-Mancilla J, Haberer J . Adherence Measurements in HIV: New Advancements in Pharmacologic Methods and Real-Time Monitoring. Curr HIV/AIDS Rep. 2018; 15(1):49-59. PMC: 5876155. DOI: 10.1007/s11904-018-0377-0. View

14.

Marshall S, Burghaus R, Cosson V, Cheung S, Chenel M, DellaPasqua O . Good Practices in Model-Informed Drug Discovery and Development: Practice, Application, and Documentation. CPT Pharmacometrics Syst Pharmacol. 2016; 5(3):93-122. PMC: 4809625. DOI: 10.1002/psp4.12049. View

15.

Kastrissios H, Blaschke T . Medication compliance as a feature in drug development. Annu Rev Pharmacol Toxicol. 1997; 37:451-75. DOI: 10.1146/annurev.pharmtox.37.1.451. View

16.

Haberer J, Ngure K, Muwonge T, Mugo N, Katabira E, Heffron R . Brief Report: Context Matters: PrEP Adherence is Associated With Sexual Behavior Among HIV Serodiscordant Couples in East Africa. J Acquir Immune Defic Syndr. 2017; 76(5):488-492. PMC: 5680116. DOI: 10.1097/QAI.0000000000001548. View

17.

Vrijens B, de Geest S, Hughes D, Przemyslaw K, Demonceau J, Ruppar T . A new taxonomy for describing and defining adherence to medications. Br J Clin Pharmacol. 2012; 73(5):691-705. PMC: 3403197. DOI: 10.1111/j.1365-2125.2012.04167.x. View

18.

Van Damme L, Corneli A, Ahmed K, Agot K, Lombaard J, Kapiga S . Preexposure prophylaxis for HIV infection among African women. N Engl J Med. 2012; 367(5):411-22. PMC: 3687217. DOI: 10.1056/NEJMoa1202614. View

19.

Grant R, Lama J, Anderson P, McMahan V, Liu A, Vargas L . Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med. 2010; 363(27):2587-99. PMC: 3079639. DOI: 10.1056/NEJMoa1011205. View

20.

Harrison R . Phase II and phase III failures: 2013-2015. Nat Rev Drug Discov. 2016; 15(12):817-818. DOI: 10.1038/nrd.2016.184. View